An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia
- 1 December 2004
- journal article
- review article
- Published by Elsevier in Controlled Clinical Trials
- Vol. 25 (6) , 598-612
- https://doi.org/10.1016/j.cct.2004.09.002
Abstract
No abstract availableKeywords
This publication has 108 references indexed in Scilit:
- Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective DisorderAmerican Journal of Psychiatry, 2002
- Industry-sponsored clinical research: a double-edged swordThe Lancet, 2001
- Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint [123I]IBZM SPECT studyPsychiatry Research: Neuroimaging, 2001
- Putting trials on trial--the costs and consequences of small trials in depression: a systematic review of methodology.Journal of Epidemiology and Community Health, 1997
- The Effects of Clozapine on Symptom Clusters in Treatment-Refractory PatientsJournal of Clinical Psychopharmacology, 1997
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophreniaClinical Therapeutics, 1995
- Changes in Single Symptoms and Separate Factors of the Schizophrenic Syndrome after Treatment with Risperidone or HaloperidolPharmacopsychiatry, 1994
- Statistics and Ethics in Surgery and AnesthesiaScience, 1977
- Evidence Favoring the Use of Anticoagulants in the Hospital Phase of Acute Myocardial InfarctionNew England Journal of Medicine, 1977